Capivasertib(Truqap) is a targeted therapy for patients with specific breast lesions and should be used strictly in accordance with the doctor's instructions. Correct use of the drug can improve efficacy and reduce the risk of adverse reactions. The following content will explain in detail its specific usage and precautions.
Instructions for use and indications of Indian Capivasertib
Recommended dosage and administration method
The standard dose of Capivasertib is 400 mg orally twice a day, about 12 hours apart, for 4 consecutive days and then 3 days of rest. The drug can be used in combination with Fulvestine, and the specific combination regimen needs to be formulated by the doctor. The time of taking the drug is not restricted by diet, but it should be avoided to use it at the same time with strong CYP3A inhibitors (such as clarithromycin). If the missed dose is less than 4 hours, it should be taken immediately; if it is more than 4 hours, skip the dose and continue to take the drug as planned.
Dose adjustment for adverse reactions
If severe hyperglycemia, diarrhea or skin adverse reactions occur, the drug should be suspended and the doctor should be contacted to adjust the dose. When used with moderate CYP3A inhibitors, the dose needs to be reduced to 320mg twice daily; when used with strong inhibitors, the drug needs to be discontinued. The generic drug produced by Laos Lucius is 160 mg*64 tablets and 200 mg*64 tablets.
Standardized medication is the core of controlling disease progression. Patients need to have regular follow-up visits and cooperate with doctors to monitor physical indicators. The following content will fully analyze the indications of Capivasertib.
Comprehensive interpretation of Capivasertib indications
Capivasertib is suitable for patients with advanced breast lesions with specific gene mutations, and its indications need to be confirmed by precise testing. The following lists the key applicable conditions and treatment plans.
Applicable population and genetic testing requirements
Patients must meet the following conditions: hormone receptor (HR) positive, HER2 negative, locally advanced or metastatic breast lesions, and genetic testing confirms the presence of PIK3CA, AKT1 or PTEN gene mutations. After failing at least one endocrine therapy, such patients can use Capivasertib in combination with fulvestrant. Fasting blood glucose and glycosylated hemoglobin tests are required before treatment to ensure that metabolic indicators are stable.
Clinical significance of combined medication
Capivasertib enhances the efficacy of fulvestrant by inhibiting the AKT signaling pathway and delaying the progression of lesions. Clinical trials have shown that combined medication can significantly prolong progression-free survival. For premenopausal women or male patients, LHRH agonists should be used simultaneously to inhibit hormone secretion and improve the therapeutic effect.
Clarifying the indications helps to screen the patient population suitable for treatment. The following content will explain the contraindications and high-risk groups of Capivasertib.
Contraindications of Capivasertib
Capivasertib has specific contraindications, and the patient's health status must be strictly evaluated before use. Ignoring contraindications may cause serious complications.
Contraindications for pregnant and lactating women
Animal experiments have shown that Capivasertib may cause fetal malformations or miscarriage, and pregnant women are prohibited from using it. Lactating women need to stop breastfeeding to avoid the drug affecting the baby through breast milk. Women with fertility plans need to take effective contraceptive measures during treatment and within 1 month after stopping the drug, and male patients need to use contraception within 4 months after stopping the drug.
Restrictions for patients with hepatic and renal insufficiency
Patients with severe hepatic insufficiency (bilirubin>3 times the upper limit of normal value) or renal failure (creatinine clearance <15mL/min) are prohibited. Patients with mild hepatic and renal insufficiency need to closely monitor drug concentrations and adverse reactions and adjust the dose if necessary. Liver enzymes, creatinine and blood routine indicators need to be regularly reviewed during treatment.
Patients and their families should fully understand the risks of the drug and strictly follow the doctor's advice. If persistent hyperglycemia, severe diarrhea or rash occurs, seek medical attention immediately. Through scientific management and regular follow-up, the therapeutic effect of Capivasertib can be maximized and the quality of life of patients can be improved.
